Cogent Biosciences Inc COGT
Stock price quote for Cogent Biosciences Inc, symbol COGT, Nasdaq Stock Exchange.
Quote data is updated continously during trading hours.
|
Cogent Biosciences Inc Symbol: COGT Exchange: NSDQ
|
| Most Recent Activity |
Activity Today |
Yearly Statistics |
|
|
|
|
All market data is delayed by 15 minutes.
Stock price quotations are updated continuously. Click reload to refresh this display.
[Daily],
[Weekly]
and [Monthly] stock price charts are available for Cogent Biosciences Inc
Most Recent HeadlinesMNA: Dec 9th, 2024, 00:45Length: 11599 Cogent Biosciences Announces Positive Updated Data From Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib In Patients With Advanced Systemic Mastocytosis (Advsm)MNA: Dec 8th, 2024, 22:50Length: 11599 Cogent Biosciences Announces Positive Updated Data From Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib In Patients With Advanced Systemic Mastocytosis (Advsm)MNA: Dec 8th, 2024, 21:55Length: 11599 Cogent Biosciences Announces Positive Updated Data From Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib In Patients With Advanced Systemic Mastocytosis (Advsm)MNA: Dec 8th, 2024, 21:00Length: 11599 Cogent Biosciences Announces Positive Updated Data From Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib In Patients With Advanced Systemic Mastocytosis (Advsm)MNA: Dec 8th, 2024, 20:06Length: 11599 Cogent Biosciences Announces Positive Updated Data From Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib In Patients With Advanced Systemic Mastocytosis (Advsm)MNA: Dec 8th, 2024, 19:09Length: 11599 Cogent Biosciences Announces Positive Updated Data From Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib In Patients With Advanced Systemic Mastocytosis (Advsm)MNA: Dec 8th, 2024, 18:14Length: 11599 Cogent Biosciences Announces Positive Updated Data From Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib In Patients With Advanced Systemic Mastocytosis (Advsm)MNA: Dec 8th, 2024, 17:17Length: 11599 Cogent Biosciences Announces Positive Updated Data From Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib In Patients With Advanced Systemic Mastocytosis (Advsm)MNA: Dec 8th, 2024, 16:20Length: 11599 Cogent Biosciences Announces Positive Updated Data From Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib In Patients With Advanced Systemic Mastocytosis (Advsm)MNA: Dec 8th, 2024, 15:27Length: 11599 Cogent Biosciences Announces Positive Updated Data From Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib In Patients With Advanced Systemic Mastocytosis (Advsm)
Market data delivered to TradingCharts.com, Inc. by Barchart.com.
Although it is believed that information provided is accurate, no guarantee is made.
|
